申请人:Resverlogix Corporation
公开号:US08053440B2
公开(公告)日:2011-11-08
The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
本公开涉及化合物,其用于调节载脂蛋白A-I(ApoA-I)的表达,并且它们的用途是用于治疗和预防心血管疾病和相关疾病状态,包括胆固醇或脂质相关紊乱,例如动脉粥样硬化。